Tien Liang BioTech Co., Ltd. (TPEX:4127)
Taiwan · Delayed Price · Currency is TWD 35.25
+1.75 (5.22%)
Jan 22, 2026, 1:30 PM CST
Tien Liang BioTech Revenue
Tien Liang BioTech had revenue of 136.22M TWD in the quarter ending September 30, 2025, with 40.36% growth. This brings the company's revenue in the last twelve months to 467.02M, up 12.55% year-over-year. In the year 2024, Tien Liang BioTech had annual revenue of 385.21M, down -16.26%.
Revenue (ttm)
467.02M
Revenue Growth
+12.55%
P/S Ratio
3.28
Revenue / Employee
5.31M
Employees
61
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.21M | -74.79M | -16.26% |
| Dec 31, 2023 | 459.99M | -68.53M | -12.97% |
| Dec 31, 2022 | 528.52M | -42.79M | -7.49% |
| Dec 31, 2021 | 571.32M | 140.23M | 32.53% |
| Dec 31, 2020 | 431.08M | -4.78M | -1.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.27B |
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 859.77M |
| Allied Biotech | 821.81M |
| Prince Pharmaceutical | 798.27M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 654.88M |